In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Preparing for the decline of oil and gas in Canada
Inside the sparkly, hard-core world of competitive cheer
Ukrainian refugee children find a new start in Canada
Is multi-generational housing the next big trend?
How a mutiny weakened Putin’s strongman image
A $50-million fine in Canada’s bread price-fixing scandal
Is Canada’s waste program trash?
Canada’s ministers are missing critical memos
The altercation that led to a Supreme Court Justice resigning
The sexual assault survivors fighting their own publication bans
China’s control over Canada’s very rare and important mineral
B.C. is sending thousands of cancer patients to the U.S.
Secret Canada: The 'black hole' of Canada's immigration system
The reality of how your chocolate gets made
Here’s why millennials are drowning in debt
Helping people escape the world’s harshest anti-LGBTQ laws
Pressure builds for public inquiry after special rapporteur quits
Secret Canada: The information laws governments keep breaking
How Greece got its economic groove back
Canada’s unprecedented wildfire season
Create your
podcast in
minutes
It is Free
Morning Wire
The Daily
Up First
Dobré ráno | Denný podcast denníka SME
Today, Explained